Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C

Hepatology Research

Volumn 37, Issue 8, 2007, Pages 579-595

  Teixeira, Rosângela ^a   Marcos, Luis A ^b   Friedman, Scott L ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF TEXAS   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antifibrotic therapy; Chronic hepatitis C; Immuno pathogenesis; Liver fibrosis

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIOXIDANT; CAMOSTAT MESILATE; COLLAGEN TYPE 1; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; GLIOTOXIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMATINIB; MATRIX METALLOPROTEINASE; NITRIC OXIDE DONOR; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; RAPAMYCIN; RIBAVIRIN; S ADENOSYLMETHIONINE; SCATTER FACTOR; SILYMARIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

APOPTOSIS; CELL ACTIVATION; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE THERAPY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INDIVIDUALIZATION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER INJURY; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; REVIEW; STELLATE CELL; TREATMENT PLANNING; WOUND HEALING;

EID: 34347332337     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00085.x     Document Type: Review

References (190)

1. World Health Organization. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999; 74: 425-7.
2. Gish RG. Hepatocellular carcinoma: Overcoming challenges in disease management. Clin Gastroenterol Hepatol 2006; 4: 252-61.
3. Organ Procurement and Transplantation Network. National Data Reports. Current waiting list by organ and diagnosis as of March 16, 2007. Richmond, VA: United Network for Organ Sharing, 2007. Accessed 22 March 2007. Available from: http://www.optn.org/latestData/rptData.asp
4. Vogt M, Lang T, Frosner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.
5. Rodger A, Roberts S, Lanigan A et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-7.
6. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
7. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 720-39.
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
9. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
10. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-34.
11. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am J Transplant 2006; 6: 12-19.
12. Davis GL, Albrigh JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
13. Everson GT. Treatment of hepatitis C in patients who have decompensated cirrhosis. Clin Liver Dis 2005; 9: 473-86.
14. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.
15. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-14.
16. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized controlled trial. Lancet 2001; 358: 958-65.
17. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir Dipivoxil 438 Study Group. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Internal Med 2004; 140: 346-55.
19. Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha-2b and ribavirin: An open-label series. Transplantation 2004; 77: 190-4.
20. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005; 11: 479-89.
21. Chalasani N, Manzarbeitia C, Ferenci P et al. Pegasys Transplant Study Group. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005; 41: 289-98.
22. Heydtmann M, Freshwater D, Dudley T et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006; 6: 825-33.
23. Sangik OH, Afdhal NH. Antiviral therapy for treatment naïve patients with hepatitis C. Infect Dis Clinics North Am 2006; 20: 99-113.
24. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005; 3: S113-17.
25. Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J Gastroenterol Hepatol 2006; 21: S88-91.
26. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Prac Gastroenterol Hepatol 2004; 1: 98-105.
27. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-72.
28. Knittel T, Kobold D, Saile B et al. Rat liver myofibroblasts and HSCs: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999; 117: 1205-21.
29. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 28: 2247-50.
30. McCrudden R, Iredale JP. Liver fibrosis, the HSC and tissue inhibitors of metalloproteinases. Histol Histopathol 2000; 15: 1159-68.
31. Kisseleva T, Uchinami H, Feirt N et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45: 429-38.
32. Forbes SJ, Russo FP, Rey V et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-63.
33. Forbes SJ, Alison MR. Side population (SP) cells: Taking center stage in regeneration and liver cancer? Hepatology 2006; 44: 23-6.
34. Russo FP, Alison MR, Bigger BW et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-21.
35. Duffield JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
36. Friedman SL. Mac the knife? Macrophages: The double-edged sword of hepatic fibrosis. J Clin Invest 2005; 115: 29-32.
37. Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: Report of the Third AASLD Single Topic Conference. Hepatology 2007; 45: 242-9.
38. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-36.
39. Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H. Hepatitis C virus: Detection of intracellular virus particles by electron microscopy. Hepatology 1996; 23: 205-9.
40. Wong DK, Dudley DD, Dohrenwend PB et al. Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J Virol 2001; 75: 1229-35.
41. Caussin-Schwemling C, Schmitt C, Stoll-Keller F. Study of the infection of human blood derived monocyte/ macrophages with hepatitis C virus in vitro. J Med Virol 2001; 65: 14-22.
42. Arrieta JJ, Rodriguez-Inigo E, Ortiz-Movilla N et al. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol 2001; 158: 259-64.
43. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001; 313: 451-64.
44. Moriishi K, Matsuura Y. Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 2003; 14: 285-97.
45. Flint M, Quinn ER, Levy S. In search of hepatitis C virus receptor(s). Clin Liver Dis 2001; 5: 873-93.
46. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
47. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74: 10055-62.
48. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10: S59-67.
49. Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-9.
50. Mita E, Hayashi N, Iio S et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468-74.
51. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002; 160: 641-54.
52. McLauchlan J. Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes. J Viral Hepat 2000; 7: 2-14.
53. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-031.
54. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004; 126: 529-40.
55. Lai MM. Hepatitis C virus proteins: Direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 2002; 122: 568-71.
56. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000; 106: 1239-49.
57. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002; 7: D1899-914.
58. Olaso E, Salado C, Egilegor E et al. Proangiogenic role of tumor-activated HSCs in experimental melanoma metastasis. Hepatology 2003; 37: 674-85.
59. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 1999; 6: 165-81.
60. Bureau C, Bernad J, Chaouche N et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem 2001; 276: 23077-83.
61. Liaw YF, Lee CS, Tsai SL et al. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368-73.
62. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-65.
63. Cooper S, Erickson AL, Adams EJ et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-49.
64. Gruner NH, Gerlach TJ, Jung MC et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 1528-36.
65. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512.
66. Takaki A, Wiese M, Maertens G et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
67. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2003; 7: 89-105.
68. Shirai M, Okada H, Nishioka M et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994; 68: 3334-42.
69. Battegay M, Fikes J, Di Bisceglie AM et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69: 2462-70.
70. Hiroishi K, Kita H, Kojima M et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25: 705-12.
71. Gruener NHF, Lechner MC, Jung H et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 5550-8.
72. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-406.
73. Koziel MJ, Dudley D, Wong JT et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339-44.
74. Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993; 151: 4189-99.
75. Wong DK, Dudley DD, Afdhal NH et al. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160: 1479-88.
76. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3: 51-62.
77. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120: 512-24.
78. Wedemeyer H, Xiao-Song H, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-58.
79. Jones NA, Wei X, Flower DR et al. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 2004; 200: 1243-56.
80. El-Kady IM. Assessment of humoral immune response in patients with chronic hepatitis C virus infection. Egypt J Immunol 2004; 11: 141-7.
81. Golden-Mason L, Rosen HR. Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? Liver Transpl 2006; 12: 363-72.
82. Liu ZX, Govindarajan S, Okamoto S, Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol 2000; 164: 6480-6.
83. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-30.
84. Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. NK cells suppressed HCV ribonucleic acid expression in HCV replicon-containing hepatic cells. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004; 76: 1171-9.
85. Melhem A, Muhanna N, Bishara A et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006; 45: 60-71.
86. Bonavita MS, Franco A, Paroli M et al. Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int J Tissue React 1993; 15: 11-16.
87. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 109: 451-7.
88. Kawarabayashi N, Seki S, Hatsuse K et al. Decrease of CD56 + T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000; 32: 962-9.
89. + natural killer T cells in chronic hepatitis C viral infection. J Hepatol 2002; 37: 101-8.
90. Gabrielli A, Sambo P, Zhang ZX et al. Humoral immune response and natural killer activity in patients with mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl 13): S95-9.
91. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-4.
92. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepatol 2000; 32: 673-84.
93. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
94. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-56.
95. Morishima C, Paschal DM, Wang CC et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006; 43: 573-80.
96. Safadi R, Ohta M, Alvarez CE et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127: 997-1000.
97. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-52.
98. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220.
99. Biron CA. Interferons alpha and beta as immune regulators - a new look. Immunity 2001; 14: 661-4.
100. Everson GT, Jensen DM, Craig JR et al. Efficacy of interferon treatment for patients with chronic hepatitis C comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999; 30: 271-6.
101. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy including quantitative assessment by a morphometric method. J Gastroenterol 2000; 35: 1105-11.
102. Cook RT, Li F, Vandersteen D, Ballas ZK, Cook BL, LaBrecque DR. Ethanol and natural killer cells. I. Activity and immunophenotype in alcoholic humans. Alcohol Clin Exp Res 1997; 21: 974-80.
103. Laso FJ, Madruga JI, Giron JA et al. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 1997; 25: 1096-100.
104. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004; 24: 305-15.
105. Gao B. Alcohol and hepatitis virus interactions in liver pathology. In: Preedy VR, Watson RR, eds. Comprehensive Handbook of Alcohol Related Pathology. New York: Elsevier Academic, 2005; 819-32.
106. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
107. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 2003; 37: 493-503.
108. Patel K, Norris S, Lebeck L et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006; 43: 241-9.
109. Kuzushita N, Hayashi N, Moribe T et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240-4.
110. Asti M, Martinetti M, Zavaglia C et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999; 29: 1272-9.
111. Renou C, Halfon P, Pol S et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-90.
112. Tillmann HL, Chen DF, Trautwein C et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001; 48: 714-18.
113. Hue S, Cacoub P, Renou C et al. Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 2002; 186: 106-9.
114. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237-45.
115. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-24.
116. Kuzushita N, Hayashi N, Kanto T et al. Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Gastroenterology 1999; 116: 1149-54.
117. Romero-Gomez M, Montes-Cano MA, Otero-Fernandez MA et al. SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut 2004; 53: 446-50.
118. Huang H, Shiffman ML, Cheung RC et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 1679-87.
119. Reynolds WF, Patel K, Pianko S, Blatt LM, Nicholas JJ, McHutchison JG. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. Genes Immun 2002; 6: 345-9.
120. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41.
121. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
122. Bedossa P, Dargere D, Paradis V. Sampling variability of liver biopsy in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
123. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.
124. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42: S22-36.
125. Bismuth FI, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with chronic hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
126. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
127. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
128. Rosenberg WM, Voelker M, Thiel R et al. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127: 2004-13.
129. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Banhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
130. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43: S113-20.
131. Xu XQ, Leow CK, Lu X et al. Molecular classification of liver fibrosis in a rat model by proteomics and bioinformatics. Proteomics 2004; 4: 3235-45.
132. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequence-based total serum protein glycomics. Nat Med 2004; 10: 429-34.
133. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 2005-13.
134. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
135. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurements of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
136. Kazemi F, Kettaneh A, N'kontchou G et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45: 230-5.
137. Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-45.
138. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006; 43: S82-8.
139. Friedman SL, Arthur MJP. Reversing hepatic fibrosis. Sci Med 2002; 8: 194-205.
140. Toyama T, Nakamura H, Harano Y et al. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 2004; 324: 697-704.
141. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38: S38-53.
142. Issa R, Zhou X, Constandinou CM et al. Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-808.
143. Horani A, Muhanna N, Pappo O et al. The beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G628-38.
144. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat HSCs and Kupffer cells. Hepatology 1998; 27: 1265-74.
145. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of D -alpha-tocopherol on HSC activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-73.
146. Mallat A, Preaux SM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 1003-10.
147. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994; 42: 660-70.
148. Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-30.
149. Galli A, Crabb DW, Ceni E et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and HSC activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40.
150. Kon K, Ikejima K, Hirose M et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002; 291: 55-61.
151. Marra F, Efsen E, Romanelli RG et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proiflammatory actions in HSCs. Gastroenterology 2000; 119: 466-78.
152. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
153. Chen MH, Chen JC, Tsai CC et al. The role of TGF-β1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model. J Ethnopharmacol 2005; 97: 7-13.
154. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
155. Bearzi I, Mandolesi A, Arduini F, Costagliola A, Ranaldi R. Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. Anal Quant Cytol Histol 2006; 28: 137-47.
156. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha Akt inativation. Clin Cancer Res 2004; 10: 681-90.
157. Hwang RF, Yokoi K, Bucana CD et al. Inhibition of PDGF receptor phosphorylation by STI571 reduces growth and metastasis of human pancreatic carcinoma in orthotopic nude mouse model. Clin Cancer Res 2003; 9: 6534-44.
158. Daniels CE, Wikes MC, Edens M et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-16.
159. Wolf AM, Wolf D, Rumpold H et al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 2005; 102: 13622-7.
160. Yoshiji H, Noguchi R, Kuriyama S et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288: 907-13.
161. Neef M, Ledermann M, Saegesser H et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006; 44: 167-75.
162. Yoshiji H, Kuriyama S, Noguchi R et al. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 2006; 17: 899-904.
163. Okuno M, Moriwaki H, Muto Y, Kojima S. Protease inhibitors suppress TGF-beta generation by hepatic stellate cells. J Hepatol 1998; 29: 1031-2.
164. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000; 32: 247-55.
165. Lavoie JL, Sigmund CD. Minireview. Overview of the renin-angiotensin system: An endocrine and paracrine system. Endocrinology 2003; 144: 2179-83.
166. Ruiz-Ortega M, Lorenzo O, Ruperez M et al. Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 2001; 38: 1382-7.
167. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409-18.
168. Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. M Mol Cell Cardiol 2002; 34: 1435-42.
169. Arroyo V, Bosch J, Mauri M et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979; 9: 69-73.
170. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002; 123: 1667-76.
171. Bataller R, Sancho-Bru P, Gines P. The renin-angiotensin system and liver fibrosis. Therapeutic implications. In: Arroyo V, Forns X, Garcia-Pagan JC, Rodes J, eds. Progress in the Treatment of Liver Diseases. Barcelona: Ars Medica, 2003; 209-16.
172. Brown NJ, Vaughan DE, Fogo AB. The renin-angiotensin aldosteron system and fibrinolysis in progressive renal disease. Semin Nephrol 2002; 22: 399-406.
173. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 2001; 135: 153-60.
174. Bataller R, Gines P, Nicolas JM et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
175. Terui Y, Saito T, Watanabe H et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022.
176. Yoshiji H, Kuriyama S, Noguchi R et al. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol Res 2006; 36: 124-9.
177. Schuppan D, Mauer M, Krebs A, Hahn EG. Antifibrogenic treatment -present status and future directions. In: Arroyo V, Bosch J, Bruix J, Gines P, Navasa M, Rodes J, eds. Therapy in Hepatology. Barcelona: Ars Medica, 2001; 395-405.
178. Rockey DC. Vascular mediators in the injured liver. Hepatology 2003; 37: 4-12.
179. Rockey DC, Weisigir RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implication for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-40.
180. Yokomori H, Oda M, Ogi M et al. Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver. Liver 2001; 21: 114-22.
181. Yokomori H, Oda M, Yasogawa Y et al. Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver. Am J Pathol 2001; 159: 1353-62.
182. Cho JJ, Hocher B, Herbst H et al. An oral endothelin A receptor antagonist blocks collagen synthesis and deposition in advanced rat secondary fibrosis. Gastroenterology 2000; 118: 1169-78.
183. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-8.
184. Angus PW. Role of endothelin in systemic and portal resistance in cirrhosis. Gut 2006; 55: 1230-2.
185. Wright MC, Issa R, Smart DE et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-98.
186. Oakley F, Mann J, Nailard S et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. Am J Pathol 2005; 166: 695-708.
187. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: Implications for wound healing and fibrogenesis. Cell Death Differ 2007; 14: 275-85. Epub ahead of print PMID: 16763620.
188. Habens F, Srinivasan N, Oakley F, Mann DA, Ganesan A, Packham G. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 2005; 10: 481-91.
189. Salgado S, Garcia J, Vera J et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000; 2: 545-51.
190. Siller-Lopez F, Sandoval A, Salgado S et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004; 126: 1122-33.